MY-TRAC

  • Research type

    Research Study

  • Full title

    A pilot study of the feasibility and utility of a fitness tracker to explore activity levels in myeloma patients undergoing autologous stem cell transplant.

  • IRAS ID

    338448

  • Contact name

    Kevin Boyd

  • Contact email

    kevin.boyd@rmh.nhs.uk

  • Sponsor organisation

    The Royal Marsden Hospital

  • Duration of Study in the UK

    1 years, 8 months, 6 days

  • Research summary

    Multiple myeloma is a type of bone marrow cancer, making up about 2% (6,000) of all new cancer cases in the UK each year. A common treatment for myeloma is an autologous stem cell transplant (ASCT), where high doses of chemotherapy are used to destroy as many cancer cells as possible. Then, stem cells (early-stage cells that can develop into different types of blood cells) are put into your body to help your bone marrow make new, healthy blood cells. At the Royal Marsden Hospital, we perform around 100 transplants for myeloma patients annually. However, this treatment can cause significant side effects and affect the quality of life for several months.

    Myeloma patients often experience a high number of symptoms and a lower quality of life, which can vary greatly from person to person. We already know that checking your fitness and activity levels is important to see if you are fit enough for treatment and helps your doctor predict how the treatment might affect you. Our study aims to track various aspects of your activity, including total daily steps, distance walked, heart rate, sleep patterns, blood oxygen levels, and skin temperature, before, during, and after your transplant.

    We want to find out if using wearable devices is a practical way to collect this kind of information for future research. We also want to see if these activity levels correlate with other measures of patient well-being.

  • REC name

    South Central - Oxford B Research Ethics Committee

  • REC reference

    24/SC/0214

  • Date of REC Opinion

    18 Jun 2024

  • REC opinion

    Favourable Opinion